CJC-1295 / Ipamorelin10mg
Blend of CJC-1295 (mod GRF 1-29), Ipamorelin
CJC-1295 / Ipamorelin Blend Canada — 10 mg, 20 mg Lyophilized Vials
Dual GHRH / GHS-R Research Blend
CJC-1295 + Ipamorelin is commonly studied for its combined role in modulating growth hormone signaling pathways and supporting pulsatile GH release in research models. It’s often explored for its effects on recovery dynamics, tissue maintenance, and overall metabolic regulation within controlled laboratory settings.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
CJC-1295 + Ipamorelin is a dual-peptide research formulation combining a growth hormone–releasing hormone (GHRH) analogue with a selective ghrelin receptor (GHS-R1a) agonist. It is developed for controlled laboratory investigation involving hypothalamic-pituitary signaling systems.
In scientific literature, CJC-1295 is studied in models examining GHRH receptor activation pathways, while ipamorelin is evaluated for its interaction with ghrelin receptor signaling frameworks. Together, the blend is researched in experimental systems exploring coordinated receptor-mediated endocrine signaling under in vitro and preclinical conditions.
Third-party tested for purity, identity, quantity.
This blend integrates two peptides studied within endocrine signaling research frameworks. CJC-1295 is evaluated in GHRH receptor activation models, while ipamorelin is examined in ghrelin receptor interaction systems. Experimental studies assess their combined behavior within hypothalamic-pituitary axis signaling environments under controlled laboratory conditions.
Research publications have explored receptor interaction dynamics and pathway-level regulatory mechanisms associated with GHRH and GHS-R signaling systems.
CJC-1295 was developed during investigations into stabilized GHRH analogues, while ipamorelin emerged from research into selective growth hormone secretagogues targeting the ghrelin receptor.
The combined formulation reflects laboratory interest in coordinated receptor pathway research involving both GHRH and GHS-R signaling mechanisms.
Laboratory investigations involving CJC-1295 and ipamorelin have focused on GHRH and ghrelin receptor activation models, hypothalamic-pituitary axis signaling, and endocrine regulatory pathway interaction systems. Research frameworks evaluate coordinated receptor-mediated signaling dynamics under controlled in vitro and preclinical conditions.
4 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Howard 1996. The work appeared in Science. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Howard 1996. The work appeared in Science. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Howard 1996. The work appeared in Science. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Howard 1996. The work appeared in Science. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 3 primary papers published between 1996 and 2006 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for CJC-1295 / Ipamorelin Blend, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
CJC-1295 / Ipamorelin Blend is also referred to as CJC/ipa, the classic stack.
CJC-1295 / Ipamorelin Blend is commonly described online in connection with muscle growth, fat loss and improved recovery. In the research literature the same compound is filed under GHRH receptor activation models, ghrelin receptor signaling studies and hypothalamic-pituitary axis research.
The 3 papers cited on this page, published between 1996 and 2006 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Each strength of CJC-1295 / Ipamorelin Blend carries its own lot code and its own certificate — CJIP-CA-26F-10, CJIP-CA-26G-20 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.
Researchers who buy CJC-1295 / Ipamorelin Blend in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
CJC-1295 / Ipamorelin Blend is a co-lyophilized blend — more than one compound freeze-dried together in a single vial. Handling follows the least stable component rather than an average, and the same is true of storage: the constraint that binds is whichever compound in the vial is most sensitive.
Reconstituting a blend does not separate its components, so a blend cannot be split into its parts after the fact. That is why per-component content verification matters more here than a single blended purity figure — the ratio inside the vial is fixed at manufacture and cannot be corrected downstream.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 5mg of CJC-1295 and 5mg of ipamorelin, totaling 10mg of lyophilized peptide blend. Independent third-party testing verifies purity, identity, and batch composition.
The vial contains only the lyophilized peptide blend. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 91(3):799–805.
PubMedIpamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 139(5):552–561.
PubMedA receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273(5277):974–977.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$144.95CAD
